ReviewJournal of neuro-oncology2009

Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma.

R E KastPubMed ↗Publisher ↗

No numbers read from the abstract.